Ultime notizie per Cytek Biosciences (NASDAQ:CTKB) Azioni

Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Cytek Biosciences Inc

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and raises the price target from $19 to $20.

News

Price Target

Analyst Ratings

PSTV

Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) with a Market Perform and lowers the price target from $75 to $73.

BANR

Keefe, Bruyette & Woods Maintains Market Perform on Banner, Lowers Price Target to $73

Keefe, Bruyette &amp; Woods analyst Kelly Motta upgrades F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) from Market Perform to Outperform and maintains the price target from $16.5 to $16.5.

Upgrades

Keefe, Bruyette & Woods Upgrades F N B to Outperform, Maintains Price Target to $16.5

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) with a Buy and raises the price target from $19 to $19.5.

PAVM

Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $19.5

Baird analyst Jonathan Komp upgrades Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) from Neutral to Outperform and maintains the price target from $15 to $15.

Baird Upgrades Wolverine World Wide to Outperform, Maintains Price Target to $15

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and raises the price target from $7 to $7.5.

LUCD

Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $7.5

Investar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISTR#NASDAQ">ISTR</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.43 by 48.84 percent. This is a 48.84 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $20.36 million which beat the analyst consensus estimate of $19.90 million by 2.29 percent. This is a 10.11 percent decrease over sales of $22.65 million the same period last year.

Earnings

ISTR

Investar Holding Q1 2025 Adj EPS $0.64 May Not Be Comparable To $0.43 Estimate, Sales $20.36M Beat $19.90M Estimate

NESR

NESR Breaks Ground on 180,000m² Facility At King Salman Energy Park, Pioneering Innovation In Saudi Arabia's Oilfield Services

Global real estate investment company Kennedy Wilson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KW#NYSE">KW</a>) has partnered with Tokyu Land US Corporation, a wholly owned subsidiary of Tokyu Land Corporation (Tokyu), one of Japan's largest real estate developers, to launch a new preferred equity and mezzanine real estate investment platform. The expanded credit solution focus will further scale Kennedy Wilson's thriving credit platform.
Kennedy Wilson and Tokyu will target over $200 million in investments with a focus on preferred equity investments and mezzanine loans to high-quality sponsors across multifamily and industrial projects nationwide. The platform is targeting markets with strong and growing local economies, attractive local amenities, and proximity to employment prospects. The platform's target investment size will generally range between $10 million and $50 million. Each investment within the platform will be approved by both Tokyu and Kennedy Wilson and Kennedy Wilson will hold 10% of the venture.

Kennedy Wilson Partners with Tokyu Land For New $200M Real Estate Investment Focus

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) co-founder&nbsp;Vitalik Buterin&nbsp;proposed a long-term solution Sunday to improve the scalability and efficiency of the network&#8217;s execution layer, one that handles smart contracts and transactions.
What Happened: In a blog post, Buterin <a href="https://ethereum-magicians.org/t/long-term-l1-execution-layer-proposal-replace-the-evm-with-risc-v/23617">suggested </a>replacing the&nbsp;Ethereum Virtual Machine contract&nbsp;language with the open-source RISC-V instruction&nbsp;set architecture. This, he argued, would address long-term scaling bottlenecks like keeping block production competitive and enhancing the efficiency of zero-knowledge EVM proving—a vital feature that enables off-chain computation and verification of transactions.
Buterin theorized that implementing the said proposal could, in limited cases, generate efficiency gains of over 100x.
See Also: <a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"></a><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44891685/gary-black-shares-polymarket-data-says-trump-tariffs-have-pushed-odds-of-2025-recession-to-57">Gary Black Shares Polymarket Data, Says Trump Tariffs Have Pushed Odds Of 2025 Recession To 57%</a>
Why It Matters: Buterin&#8217;s proposal comes at a time when the Ethereum base layer was battling a sharp dip in transaction activity and fees.
According to Etherscan, ETH&#8217;s average transaction fees have <a href="https://etherscan.io/chart/avg-txfee-usd">slipped </a>to levels not seen since May 2020. Typically, this happens due to <a href="https://www.benzinga.com/money/ethereum-gas-fees">low network demand</a>. 
Since a portion of the transaction fees is burned to add deflationary pressure to ETH, the drop in fees resulted in a lower number of ETH removed from circulation and, subsequently, inflation, <a href="https://ultrasound.money/?timeFrame=since_merge">according </a>to Ultrasound Money.
Analysts interviewed by Benzinga attributed this to the rise of Layer-2 blockchains and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37667987/ethereum-dencun-upgrade-drops-layer-2-fees-by-99">Dencun Upgrade</a>, which significantly reduced transaction costs on L2s. This resulted in on-chain activity being diverted away from the Ethereum foundation chain.
Price Action: At the time of writing, Ethereum was exchanging hands at $1,644.66, up 3.28% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.&nbsp;Year-to-date, the coin has plunged more than 50%.
Read Next
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44890965/shiba-inu-team-issues-major-anti-scam-alert-heres-what-you-need-to-know">Shiba Inu Team Issues Major Anti-Scam Alert: Here&#8217;s What You Need To Know</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>
Image Via Shutterstock/VPLAB

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$ETH

Vitalik Buterin Suggests Major Overhaul To Improve Ethereum's Network Efficiency As Transaction Fees Plunge To 5-Year Lows

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and raises the price target from $7 to $7.25.

ATOS

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25

General

HITI

High Tide Opens New Canna Cabana Retail Stores In Cochrane, Alberta

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>, ACONW)),&nbsp;a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates."
"Chronic low back pain is a complex problem that is complicated to diagnose," said Doug Beall, MD, Chief of Radiology Services, Clinical Radiology of Oklahoma and co-author.&nbsp;"I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. The profound conclusions within this important paper will not only benefit surgical intervention, but also my non-surgical colleagues in Pain Management and Interventional Radiology. Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography."
ClinicoEconomics and Outcomes Research&nbsp;is a&nbsp;peer-reviewed&nbsp;healthcare journal&nbsp;focusing on covering the economic impact of health policy and health systems organization. The journal was established in 2009 and is published by&nbsp;Dove Medical Press.
"We are pleased with the cost-effectiveness results illustrated in this important paper," said Ryan Bond, Chief Strategy Officer at Aclarion. "We believe the results demonstrating Nociscan's economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend, in other words, the value in healthcare."
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain.

ACON

Aclarion's AI-Powered Nociscan Proves More Cost-Effective for Chronic Back Pain Diagnosis

Offerings

DOMH

Dominari Holdings  Filed For Offering Of Up To 13.94M Shares By Selling Stockholders

Earnings Misses

Ennis Q4 2024 GAAP EPS $0.35 Misses $0.37 Estimate, Sales $92.701M Miss $95.600M Estimate

Ascendiant Capital analyst Edward Woo maintains Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) with a Buy and lowers the price target from $13 to $12.

PHUN

Ascendiant Capital Maintains Buy on Phunware, Lowers Price Target to $12

Target Launches First Standalone Floral Owned Brand Good Little Garden

U.S. stock futures fell on Monday, following a holiday-shortened week that ended with a mixed performance on Thursday. Major benchmark indices were trading lower in the premarket session.
Chinese Ministry of Commerce <a href="https://www.benzinga.com/25/04/44891949/chinese-commerce-ministry-pledges-retaliation-against-countries-isolating-beijing-with-us-at-the-expense-of-china">warned its trading partners</a> of retaliation in case of Beijing&#8217;s isolation by the U.S. "It should be pointed out in particular that China firmly opposes any party reaching a deal at the expense of China's interests," said the Ministry spokesperson, according to a translated version of the statement.
If the trading partners try to isolate Beijing, "China will never accept it and will resolutely take countermeasures in a reciprocal manner."
Meanwhile, the 10-year Treasury bond yielded 4.36% while the two-year bond was at 3.75%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing an 89% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.91%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.06%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.18%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.86%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 1.07% to $520.79, while the QQQ declined 1.17% to $438.87, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
While several S&amp;P 500 sectors posted gains on Thursday, led by energy, consumer staples, and real estate, the broader U.S. market mostly closed lower.
The Dow Jones marked its third consecutive day of losses. All major indices finished the shortened week in the red, pressured by steep declines in technology and health care.
The downturn was largely influenced by declines in information technology stocks like Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), down around 3%, and health care stocks like UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), which plummeted over 22% after <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">disappointing earnings</a> and guidance.
Meanwhile, Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) soared over 14% on positive weight-loss drug trial data.
Economic data from Thursday showed a decline in housing starts, a drop in jobless claims, and a sharp contraction in the Philadelphia Fed Manufacturing Index.
By Thursday&#8217;s market close, the S&amp;P 500 had fallen 14.1% from its record high of 6,147.43. The Dow Jones was down 13.15% from its 52-week peak, and the Nasdaq 100 had dropped 17.84% from its high.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.13%</td>
<td>16,286.45</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.13%</td>
<td>5,282.70</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.33%</td>
<td>39,142.23</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.92%</td>
<td>1,880.62</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to the data shared by Ryan Detrick from Carson Research, &#8220;the best and worst days tend to occur near the same time.&#8221;
He cautioned the investors with a graph of best and worst days and said, &#8220;So once again, if you sell after the worst days, odds are the best days are right around the corner.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here&#39;s another way to show that the best and worst days tend to occur near the same time. So once again, if you sell after the worst days, odds are the best days are right around the corner. <a href="https://t.co/Kv1NLDbEUe">pic.twitter.com/Kv1NLDbEUe</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1914151166998462480?ref_src=twsrc%5Etfw">April 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Detrick also highlighted that after recent corrections, the S&amp;P 500&#8217;s advance/decline line has held in surprisingly well. He highlighted that the ratio was well above its January lows.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One potential positive is the S&amp;P 500&#39;s advance/decline line has held in surprisingly well. Yes, price made new lows, but the A/D line is still well above the January lows. &#x1f914; <a href="https://t.co/pBOGHx18Yg">pic.twitter.com/pBOGHx18Yg</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1914147677635326079?ref_src=twsrc%5Etfw">April 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Katusa Research underscored in an X post that the market is &#8220;approaching bubble territory,&#8221; as the S&amp;P 500 Shiller CAPE ratio, or the cyclically adjusted price-to-earnings ratio, was nearly twice its historical average of 17.58.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Shiller CAPE: Approaching Bubble Territory The Cyclically Adjusted Price-to-Earnings ratio (made by Robert Shiller) smooths out short-term earnings fluctuations By using 10 years of inflation-adjusted earnings. The current CAPE ratio stands at 34.97, more than double its… <a href="https://t.co/qgmkFxkP09">pic.twitter.com/qgmkFxkP09</a>
&mdash; Katusa Research (@KatusaResearch) <a href="https://twitter.com/KatusaResearch/status/1912948966070894869?ref_src=twsrc%5Etfw">April 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44892375/dean-of-valuation-aswath-damodaran-warns-buying-the-dip-akin-to-catching-a-falling-">&#8216;Dean Of Valuation,&#8217; Aswath Damodaran</a>, also cautioned investors against the simplistic interpretation of "buying the dip" in his latest blog post.
Damodaran warned that &#8220;buying the dip&#8221; can be like &#8220;catching a falling knife,&#8221; as an initial decline might precede a much steeper and prolonged sell-off. Instead of a one-size-fits-all approach, Damodaran outlines several distinct paths for contrarian investors:
<ul>
<li>The Value Contrarian: This investor seeks out fundamentally undervalued companies that have been unfairly punished by the market. Their focus is on intrinsic value, patiently waiting for the market to recognize the discrepancy between price and worth. Buying the dip for a value contrarian involves identifying fundamentally sound companies whose temporary price decline offers an even more attractive entry point.</li>
</ul>
<ul>
<li>The Sentiment Contrarian: This investor bets against prevailing market sentiment, often buying when fear and pessimism are rampant. They believe that markets tend to overreact, creating opportunities to profit from the eventual correction. For this type, buying the dip is about capitalizing on widespread panic, assuming the underlying fundamentals are not severely compromised.</li>
</ul>
<ul>
<li>The Catalyst-Driven Contrarian: This investor looks for companies facing temporary setbacks or negative news that they believe will eventually be resolved. They buy in anticipation of a specific catalyst that will trigger a positive re-evaluation by the market. Buying the dip here is a calculated bet on a turnaround or the dissipation of current concerns.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul>
<li>On Monday, March&#8217;s data on the U.S. leading economic indicators will be released by 10:00 a.m. ET.</li>
</ul>
<ul>
<li>On Tuesday, Philadelphia Fed President Patrick Harker will speak at 9:30 a.m., Minneapolis Fed President Neel Kashkari will speak at 2:00 p.m., and Richmond Fed President Tom Barkin will speak at 2:30 p.m. ET.</li>
</ul>
<ul>
<li>On Wednesday, Chicago Fed President Austan Goolsbee will speak at 9:00 a.m., whereas St. Louis Fed President Alberton Musalem and Fed Governor Christopher Waller speak after that at 9:30 a.m. ET.</li>
</ul>
<ul>
<li>April&#8217;s S&amp;P flash U.S. services and manufacturing PMI will be announced by 9:45 a.m., and new home sales data for March will be out by 10:00 a.m. ET.</li>
</ul>
<ul>
<li>Fed Beige Book will be out by 2:00 p.m., and Cleveland Fed President Beth Hammack will speak at 6:30 p.m. ET.</li>
</ul>
<ul>
<li>Atlanta Fed President Raphael Bostic will speak at 7:40 p.m. ET.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims for the week ended April 19, along with March&#8217;s durable-goods orders data, will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Existing home sales for March will be released by 10:00 a.m., and Minneapolis Fed President Kashkari will speak again at 5:00 p.m. ET.</li>
</ul>
<ul>
<li>On Friday, April&#8217;s final consumer sentiment data will be announced by 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Comerica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) rose 0.19% in premarket on Monday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.13 per share on revenue of $831.34 million.</li>
</ul>
<ul>
<li>AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) declined 2.47% as Wall Street expects it to report earnings of 98 cents per share on revenue of $368.55 billion after the closing bell.</li>
</ul>
<ul>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) jumped 2.90% after reporting stronger-than-expected first-quarter financial results after the closing bell on Thursday. The company said it expects second-quarter revenue of $11.04 billion and earnings per share of $6.61.</li>
</ul>
<ul>
<li>Minerals Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTX#NYSE">MTX</a>) dropped 3.28% after issuing preliminary results for the first quarter, expecting revenue of $492 million for the quarter.</li>
</ul>
<ul>
<li>HIVE Digital Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) advanced 4.03% after announcing the completion of the first 100 MW infrastructure in Paraguay.</li>
</ul>
<ul>
<li>SHF Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) zoomed 71.30% after it partnered with FundCanna to provide compliant banking and accessible credit facilities to cannabis-related businesses nationwide.</li>
</ul>
<ul>
<li>Vincerx Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) slumped 47.27% as it announced its intention to delist from Nasdaq and deregister with the SEC after receiving a non-compliance notice from Nasdaq on April 14.</li>
</ul>
<ul>
<li>Thunder Power Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) plunged 26.78% after Western Capital Resources completed its tender offer on April 17, accepting 680,087 shares or 7.7% of the former&#8217;s outstanding shares, exceeding its initial target and accommodating all valid tenders.</li>
</ul>
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) lost 26.32% as it announced an update on its share repurchase program without disclosing the exact number of shares repurchased, using its corporate funds for buyback.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 2.67% to hover around $62.30 per barrel.
Gold Spot US Dollar advanced 2.007% to hover around $3,394.03 per ounce. Its fresh record high stood at $3,396.57 per ounce. The U.S. Dollar Index spot was lower by 1.30% at the 97.9410 level.
Asian markets advanced on Wednesday, except Japan's Nikkei 225 index. India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, China&#8217;s CSI 300, Australia's ASX 200, and South Korea's Kospi index ended higher. European markets were mostly lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44891949/chinese-commerce-ministry-pledges-retaliation-against-countries-isolating-beijing-with-us-at-the-expense-of-china">Xi Jinping&#8217;s China Pledges Retaliation Against Countries Isolating Beijing By Giving Into Trump Administration&#8217;s &#8216;Unilateral Bullying,&#8217; Says It Will &#8216;Never Accept It&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Economics

Federal Reserve

Pre-Market Outlook

AIEV

HIVE

LITM

NFLX

NVDA

SHF Holdings, Inc. - Class A Common Stock

SHFS

VINC

US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert

TD Securities analyst Andrew Charles maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Buy and lowers the price target from $130 to $120.

CAVA

TD Securities Maintains Buy on Cava Group, Lowers Price Target to $120

Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>, JFBRW))), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that its wholly-owned subsidiary, Fort Products Limited ("Fort"), has submitted the Android version of its artificial intelligence (AI)-powered pest control mobile application for review on Google Play. This follows the successful completion of the development and internal testing of the mobile app, marking a major milestone as Fort transitions from internal validation towards commercial rollout.&nbsp;
The application harnesses AI to help users identify pests and recommends tailored treatments based on species, infestation severity, and user preferences. It also features curated product suggestions, including Fort's proprietary pest control solutions.
 &nbsp;

GOOGL

JFBR

Jeffs' Brands Moves Toward Commercial Rollout With AI Pest Control App On Google Play

Press Releases

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

Cytek® Biosciences Named "Overall BioTech Company of the Year" in 2024 BioTech Breakthrough Awards Program

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

Health Care

Cytek Biosciences to Participate in Upcoming Investor Conferences

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

CTKB

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Bruker

Codexis

Charles River Laboratories International, Inc. Common Stock

Charles River

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Cytek Biosciences

Notizie

Ultime notizie per Cytek Biosciences (NASDAQ:CTKB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO